Abstract:Abstract 4475 Imatinib mesylate is a selective tyrosine kinase inhibitor targeting BCR-ABL fusion protein. In the therapy of either interferon refractory or newly diagnosed chronic myeloid leukemia (CML), imatinib significantly improved the prognosis of the disease, albeit with typically mild to moderate adverse effects. In recent years, increasing attention has been focused on the skin hypopigmentation developed after the initiation of imatinib therapy, especially in Asian countries such as India, with the incidence between 33% and 85%, though sparsely reported in western countries. The inhibition of c-kit by imatinib may be a possible explanation, but the exact mechanism for this hypopigmentation caused by imatinib and its potential risk in patients is poorly understood. Here we report our clinical observation of this side effect of imatinib therapy among Chinese CML patients in our institution, as well as a brief in vitro study aiming to investigate the mechanism of the hypopigmentory effect and evaluate its potential risk. Among 116 patients who took imatinib for CML therapy, 90 of them (77.6%) had reported to develop generalized hypopigmentation or whitening in the skin. This side effect usually developed within 3 months after initiation of imatinib, persistent during the therapy, and reversible upon imatinib discontinuation, according to our interviews and observation. More interestingly, in three of these CML patients who originally had vitiligo, the cosmetic appearance seemed to be improved during imatinib therapy due to the whitening effect on normal pigmented skin areas. To further confirm and understand this side effect, we examined the impact of imatinib on cultured normal human melanocytes derived from the foreskins of healthy Chinese adults. Melanocytes were treat with various concentrations of imatinib (1~16 μ M) for different periods of time (1~7 days). Cell proliferation and apoptosis were detected by cell counting kit-8 and flow cytometric assay, respectively. The melanogenic activity of the melanocytes was detected by melanin content assay and tyrosinase activity assay. Moreover, the role of stem cell factor (SCF) and its receptor c-kit in imatinib induced hypopigmentation were investigated. We found that imatinib not only concentration-dependently inhibited melanocyte proliferation in vitro (IC50=6.23 μ M), but also resulted in massive melanocyte apoptosis at concentrations higher than 8 μ M (P Disclosures: No relevant conflicts of interest to declare.

The blue palate-A case series of imatinib-related oral pigmentation and literature review

Two cases of imatinib induced oral pigmentation affecting the palate.

Hyperpigmentation Due To Prolonged Use Of Imatinib - A Case Report.

Oral Reactive Capillary Hemangiomas Induced by SHR-1210 in the Treatment of Non-Small Cell Lung Cancer: a Case Report and Literature Review

Disappearance of lentigines in a patient receiving imatinib treatment for familial gastrointestinal stromal tumor syndrome

Tyrosine Kinase Inhibitor Imatinib Mesylate Induces Generalized Skin Hypopigmentation in Chinese Patients with Chronic Myelogenous Leukemia.

Inhibitory Effects of Imatinib Mesylate on Human Epidermal Melanocytes.

Cancer Chemotherapy-associated Pigmentation of the Oral Mucosa

Imatinib mesylate-induced lichenoid drug eruption

A Phase Ii Study of Imatinib for Advanced Melanoma Patients with Kit Aberrations

Remarkable effects of imatinib in a family with young onset gastrointestinal stromal tumors and cutaneous hyperpigmentation associated with a germline KIT-Trp557Arg mutation: case report and literature overview

Oral pigmentation in physiologic conditions, post-inflammatory affections and systemic diseases

Citalopram-Induced Oral Melanotic Macules in a Female Patient and a Review of the Literature

A Review of Oral Therapies for the Treatment of Skin Hyperpigmentation

Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors

Progressive hyperpigmentation and lentigines due to KIT variants improving with imatinib

Efficacy Evaluation of Imatinib for the Treatment of Melanoma: Evidence from a Retrospective Study

Case Series with a Concise Review of the Current Literature

Resistance Mechanism of Imatinib Therapy in Gastrointestinal Stromal Tumors

Effect of imatinib on oral wound healing after extraction: A rare case report

S3601 Sapphire Shadows: A Case Series Describing Unusual Ileal Discoloration in a Veteran Population